The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
| ||||||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ADVERUM BIOTECHNOLOGIES INC | COM | 00773U108 | 808 | 74,530 | SH | SOLE | 0 | 0 | 74,530 | ||
| INTUIT | COM | 461202103 | 769 | 2,025 | SH | SOLE | 0 | 0 | 2,025 | ||
| JBG SMITH COM | COM | 46590V100 | 55,029 | 1,759,817 | SH | SOLE | 0 | 0 | 1,759,817 | ||
| OCULAR THERAPEUTIX INC | COM | 67576A100 | 629 | 30,410 | SH | SOLE | 0 | 0 | 30,410 | ||
| TRANSDIGM GROUP INC | COM | 893641100 | 9,658 | 15,607 | SH | SOLE | 0 | 0 | 15,607 | ||